Introduction
Patients and methods
Results
Negative controls (n=37) | Sera from COVID-19-positive patients (n=27) | ||||
---|---|---|---|---|---|
Early sera from COVID-19-positive patients (n=10) | Sera from negative HCoVs patients collected before the pandemic (n=13) | Sera from healthcare workers highly exposed to SARS-CoV-2 (n=14) | All (n=37) | ||
Nucleocapsid (56 kDa) | |||||
S/N ratio | 44 (29.98–64.4) | 62.1 (33–78.7) | 49.85 (34.95–70.95) | 49.85 (34.95–70.95) | 421 (214.1–666.8) |
Height | 6511 (5674–7729) | 8854 (6428–12,995) | 4934 (4397–5605) | 6100 (4586–9813) | 64,065 (32,338–121,517) |
Area | 82,169 (65588–94,895) | 124,541 (84495–147,319) | 67,780 (61427–76,234) | 79,634 (66110–128,111) | 839,470 (524,393–1,597,656) |
Spike (217 kDa) | |||||
S/N ratio | 0 | 0 | 0 | 0 | 27.9 (0–43.1) |
Height | 0 | 0 | 0 | 0 | 3174 (0–8621) |
Area | 0 | 0 | 0 | 0 | 40,699 (0–182,108) |
n=64 | AUC | Youden index | Optimal cut-off value | Sensitivity (%) | Specificity (%) | True positive (number) | True negative (number) | False positive (number) | False negative (number) |
---|---|---|---|---|---|---|---|---|---|
Nucleocapsid | |||||||||
S/N | 0.975 | 0.907 | 110.4 | 96.3 | 94.6 | 26 | 35 | 2 | 1 |
Height | 0.982 | 0.885 | 249 | 88.9 | 100 | 24 | 37 | 0 | 3 |
Area | 0.970 | 0.885 | 287 | 88.9 | 100 | 24 | 37 | 0 | 3 |
Spike | |||||||||
S/N | 0.833 | 0.667 | 0 | 66.7 | 100 | 18 | 37 | 0 | 9 |
Height | 0.833 | 0.667 | 0 | 66.7 | 100 | 18 | 37 | 0 | 9 |
Area | 0.833 | 0.667 | 0 | 66.7 | 100 | 18 | 37 | 0 | 9 |
Negative controls | Sera from patients diagnosed with others HCoVs (n=76) | Sera collected before the pandemic from patients with unknown status for HCoVs (n=266) | Sera from COVID-19-positive patients (n=223) | Total (n=602) | ||||
---|---|---|---|---|---|---|---|---|
Early sera from COVID-19-positive patients (n=10) | Sera from negative HCoVs patients collected before the pandemic (n=13) | Sera from healthcare workers highly exposed to SARS-CoV-2 (n=14) | All (n=37) | |||||
Positive sera | ||||||||
Nucleocapsid reactivity | 1 (10%) | 0 | 2 (14%) | 3 (8%) | 9 (12%) | 12 (4.5%) | 180 (81%) | 204 (34%) |
Spike reactivity | 0 | 0 | 0 | 0 | 2 (3%) | 0 | 67 (30%) | 69 (11%) |
Total | 1 (10%) | 0 | 2 (14%) | 3 (8%) | 11 (14.5%) | 12 (4.5%) | 181 (81%) | 207 (34%) |
AWB IgT number (%) | ELISA IgG number (%) | |
---|---|---|
Sera from COVID-19 positive patients (n=27) | 27 (100) | 22 (81) |
Sera from negative control group (n=37) | 3 (8) | 0 |
Early sera from COVID-19 positive patients (n=10) | 1 (10) | 0 |
Sera from healthcare workers highly exposed to SARS-CoV-2 (n=14) | 2 (14) | 0 |
Sera from negative HCoVs patients collected before the pandemic (n=13) | 0 | 0 |
Sera from patients diagnosed with other HCoVs (n=45) | 6 (13) | 0 |
Sera collected before the pandemic from patients with unknown status for HCoVs (n=88) | 5 (6) | 6 (7) |